NCT00675701

A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

A Double Blind, Randomized, Repeat-Dose, Parallel Group Study to Define the ECG Effects of Lixivaptan Using a Clinical and a Supratherapeutic Dose, Compared to Placebo and Moxifloxacin (a Positive Control), in Healthy Adult Men and Women: A Thorough ECG Study

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 298 (actual)
• Sponsor: CardioKine Inc. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1, double-blind, randomized, repeat-dose, single -dite, 4-arm parallel group study to define the ECG effect of lixivaptan using a therapeutic and supratherapeutic dose compared to placebo and moxifloxacin (a positive control in healthy adult men and women.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	placebo	capsules
DRUG	lixivaptan	capsules
DRUG	moxifloxacin	tablets

Timeline

• Start date: 2008-05-01
• Primary completion: 2008-09-01
• Completion: 2008-10-01
• First posted: 2008-05-12
• Last updated: 2011-06-21

Locations

1 site across 1 country: United States